Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Neuroimmunology

• Publication date

  2009-10-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jneuroim.2009.08.005PMID 19733918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.

  2009cited by this paper
• Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.

  2009cited by this paper
• Intranasal Insulin Ameliorates Experimental Diabetic Neuropathy

  2009cited by this paper
• Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFα single-chain Fv antibody (ESBA105) designed for local therapeutic use

  2009cited by this paper
• Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

  2009cited by this paper
• Direct transport of VEGF from the nasal cavity to brain.

  2009cited by this paper
• Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids.

  2008influential reference
• Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease

  2008influential reference
• Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease

  2008cited by this paper
• Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone

  2008cited by this paper
• Delivery of interferon-beta to the monkey nervous system following intranasal administration.

  2008cited by this paper
• Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats.

  2007influential reference
• TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study.

  2006cited by this paper
• Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice.

  2005cited by this paper
• Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.

  2004influential reference
• Intranasal insulin improves memory in humans.

  2004cited by this paper
• Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies

  2003cited by this paper
• Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

  2002cited by this paper
• Passage of amyloid β protein antibody across the blood–brain barrier in a mouse model of Alzheimer’s disease

  2002cited by this paper
• Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease.

  2002cited by this paper
• Sniffing neuropeptides: a transnasal approach to the human brain

  2002cited by this paper
• Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice

  2002cited by this paper
• Onset of multiple sclerosis associated with anti-TNF therapy

  2001cited by this paper
• Delivery of Neurotrophic Factors to the Central Nervous System

  2001cited by this paper
• Transport of drugs from the nasal cavity to the central nervous system.

  2000cited by this paper
• Changes in cytokines and neurotrophins in Parkinson's disease.

  2000cited by this paper
• Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with streptococcus pneumoniae.

  2000cited by this paper
• Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts.

  1999cited by this paper
• Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume.

  1999cited by this paper
• Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA.

  1999cited by this paper
• TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study

  1999cited by this paper
• Ocular Absorption of Pz-Peptide and Its Effect on the Ocular and Systemic Pharmacokinetics of Topically Applied Drugs in the Rabbit

  1998cited by this paper
• Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats.

  1998cited by this paper
• Penetration enhancement effect of Pz-peptide, a paracellularly transported peptide, in rabbit intestinal segments and Caco-2 cell monolayers

  1995cited by this paper
• Problems of Delivery of Monoclonal Antibodies

  1995influential reference
• Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activity

  1995cited by this paper
• Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients.

  1994cited by this paper
• Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients

  1994cited by this paper
• Paracellular transport of a proteolytically labile pentapeptide across the colonic and other intestinal segments of the albino rabbit: implications for peptide drug design

  1994cited by this paper
• Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis.

  1991cited by this paper
• Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.

  1991cited by this paper
• Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

  1991cited by this paper
• Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis.

  1991cited by this paper
• An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

  1990cited by this paper
• Tumor necrosis factor identified in multiple sclerosis brain

  1989cited by this paper
• Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations?

  1988cited by this paper
• Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey

  1986cited by this paper
• Comparative morphometry of the nasal cavity in rats and mice.

  1982cited by this paper

• Intranasal delivery systems for traumatic brain injury: Advancements and perspectives

  2025cites this paper
• A Bibliometric Analysis and Systematic Review of Research Advances in In Situ Gel Drug Delivery Systems from 2003 to 2023

  2025cites this paper
• Optimizing nasal drug delivery for peptides, proteins, and small molecules: strategic use of materials and techniques to target the CNS

  2024cites this paper
• P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy.

  2024cites this paper
• Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders

  2023cites this paper
• Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis

  2022cites this paper
• Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis

  2022cites this paper
• Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer's

  2022cites this paper
• Downregulation of CD40L–CD40 attenuates seizure susceptibility and severity of seizures

  2021cites this paper
• Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration

  2021cites this paper
• Nose-to-brain delivery of biologics and stem cells

  2021cites this paper
• Formulation strategies for nose-to-brain delivery of therapeutic molecules

  2020cites this paper
• Characterization of the novel anti-TNF-α single-chain fragment antibodies using experimental and computational approaches

  2019cites this paper
• Delivery of an anti‐transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons

  2018influential citation
• Nose-to-brain peptide delivery - The potential of nanotechnology.

  2017cites this paper
• Nervous system delivery of antilysophosphatidic acid antibody by nasal application attenuates mechanical allodynia after traumatic brain injury in rats

  2017cites this paper
• Intranasal Therapy to Stop Status Epilepticus in Prehospital Settings

  2017influential citation
• Intranasal Administration of Interleukin-1 Receptor Antagonist in a Transient Focal Cerebral Ischemia Rat Model

  2016cites this paper
• Delivery of Peptides and Proteins to the Brain Using Nano-Drug Delivery Systems and Other Formulations

  2016cites this paper
• The single‐chain anti‐TNF‐α antibody DLX105 induces clinical and biomarker responses upon local administration in patients with chronic plaque‐type psoriasis

  2016cites this paper
• Local delivery methods of therapeutic agents in the treatment of diffuse intrinsic brainstem gliomas.

  2016cites this paper
• An overview of developing TNF-α targeted therapy for the treatment of psoriasis

  2015cites this paper
• The main challenge in the treatment of neurodegenerative diseases is to overcome the restrictive mechanism of the blood brain barrier and deliver therapeutic payloads to the brain . PERSPEC TIV E

  2014cites this paper
• MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders

  2014cites this paper
• Dual Modified Liposomes for Drug and Gene Delivery to Brain

  2014cites this paper
• Precision nanomedicine in neurodegenerative diseases.

  2014cites this paper
• Brain Transit and Ameliorative Effects of Intranasally Delivered Anti-Amyloid-β Oligomer Antibody in 5XFAD Mice

  2013cites this paper
• Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn.

  2013cites this paper
• Protein therapeutics targeted at the TNF superfamily.

  2013cites this paper
• Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury: An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept

  2012cites this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cites this paper
• Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury

  2012cites this paper
• Intranasal delivery of therapeutic proteins for neurological diseases

  2011cites this paper
• Chronic Delivery of Antibody Fragments Using Immunoisolated Cell Implants as a Passive Vaccination Tool

  2011cites this paper
• Specific Binding of the Pathogenic Prion Isoform: Development and Characterization of a Humanized Single-Chain Variable Antibody Fragment

  2011cites this paper
• Potential use of single-chain Fv proteins for human and animal health

  2010cites this paper
• Rationale and development of multispecific antibody drugs

  2010cites this paper
• International Journal of Molecular Sciences the Role of Cell-penetrating Peptide and Transferrin on Enhanced Delivery of Drug to Brain

  year unknowncites this paper